Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

As the markets for weight-loss drugs develop, pharma companies are having to adapt in search of the next big thing.

1 Berkshire Hathaway (Class A) remains the most expensive stock globally at $730,000 per share in 2025. 2 Lindt & Sprüngli AG ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

Chinese Premier Li Qiang held talks with New Zealand's Prime Minister Christopher Luxon in Beijing on Friday. [Xinhua/Rao Aimin] BEIJING, June 20 (Xinhu)a -- Chinese Premier Li Qiang held talks ...

In March, Roche (ROG.S), opens new tab acquired the rights to Zealand Pharma's long-acting amylin analogue, petrelintide, in a collaboration valued at up to $5.3 billion. Similarly, Novo Nordisk ...

Basel, 20 June 2025 - Roche] study showing Lunsumio® (mosunetuzumab) administered subcutaneously in combination with Polivy® (polatuzumab vedotin) demonstrated a clinically meaningful and ...

Purdue Pharma’s $7B opioid settlement plan could get votes from victims and cities Members of the Sackler family who own the company would pay up to $7 billion and give up ownership on the company.